ALLIGATOR BIOSCIENCE AB [CBOE] news, videos and press releases
For more news please use our advanced search feature.
ALLIGATOR BIOSCIENCE AB [CBOE] - More news...
ALLIGATOR BIOSCIENCE AB [CBOE] - More news...
- Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences
- Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
- Alligator Bioscience AB: Year End report January-December 2021
- Alligator Bioscience AB: Year End report January-December 2021
- Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer
- Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty
- Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty
- Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported
- Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data
- Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication
- Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication
- Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University Rotterdam
- Bulletin from the extraordinary general meeting in Alligator Bioscience AB
- Bulletin from the extraordinary general meeting in Alligator Bioscience AB
- Alligator Bioscience AB: Interim report January-September 2021
- Alligator Bioscience AB: Interim report January-September 2021
- Notice of extraordinary general meeting in Alligator Bioscience AB
- Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline
- Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy
- Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation
- Alligator Bioscience Announces New Senior Director of Communications & Investor Relations
- Alligator Bioscience AB: Interim report January-June 2021
- Alligator Bioscience AB: Interim report January-June 2021
- Alligator Bioscience AB and Scandion Oncology A/S present promising preclinical data
- Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy
- Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017
- Bulletin from the annual general meeting in Alligator Bioscience AB on June 1, 2021
- Bulletin from the annual general meeting in Alligator Bioscience AB on June 1, 2021
- Alligator's mitazalimab shown to enhance cancer vaccine
- Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field